Increased systemic inflammatory interleukin-1ß and interleukin-6 during agitation as predictors of Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 28, Issue 3, 2013, Pages 233-241

  Honma, T ^a   Hatta, K ^b   Hitomi, Y ^a   Kambayashi, Y ^a   Hibino, Y ^a   Konoshita, T ^c   Nakamura, H ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

agitation; Alzheimer's disease; Cox regression hazard model; dementia; interleukin 1; interleukin 6

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BODY MASS INDEX; DEMENTIA, VASCULAR; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INTERLEUKIN-1BETA; INTERLEUKIN-6; JAPAN; MALE; PREDICTIVE VALUE OF TESTS; PSYCHOMOTOR AGITATION;

EID: 84873567043     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3816     Document Type: Article

References (38)

1. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, Revised 3rd edn, American Psychiatric In, Washington, DC.
2. Baqui AA, Jabra-Rizk MA, Kelley JI, et al,. 2000. Enhanced interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by LPS stimulated human monocytes isolated from HIV+ patients. Immunopharmacol Immunotoxicol 22: 401-421.
3. Bauer TT, Montõn C, Torres A, et al,. 2000. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 55: 46-52.
4. Blasko I, Schmitt TL, Steiner E, et al,. 1997. Tumor necrosis factor alpha augments amyloid beta protein (25-35) induced apoptosis in human cells. Neurosci Lett 238: 17-20.
5. Blennow K, de Leon MJ, Zetterberg H,. 2006. Alzheimer's disease. Lancet 368: 387-403.
6. Breitner JC,. 1996. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 17: 789-794.
7. Breteler MM,. 2000. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21: 153-160.
8. Chui HC, Victoroff JI, Margolin D, et al,. 1992. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42: 473-480.
9. Ciaramella A, Bizzoni F, Salani F, et al,. 2010. Increased pro-inflammatory response by dendritic cells from patients with Alzheimer's disease. J Alzheimers Dis 9: 5559-5572.
10. Craig-Schapiro R, Fagan AM, Holtzman DM,. 2009. Biomarkers of Alzheimer's disease. Neurobiol Dis 35: 128-140.
11. Flirski M, Sobow T,. 2005. Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2: 47-64.
12. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
13. Forlenza OV, Diniz BS, Talib LL, et al,. 2009. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28: 507-512.
14. Higuchi M, Hatta K, Honma T, et al,. 2010. Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease. Int J Geriatr Psychiatry 25: 604-611.
15. Holmes C, El-Okl M, Williams AL, et al,. 2003. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 788-789.
16. Hughes CP, Berg L, Danziger WL, et al,. 1982. A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572.
17. Karttunen K, Karppi P, Hiltunen A, et al,. 2011. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry 26: 473-482.
18. de Leeuw FE, de Groot JC, Oudkerk M, et al,. 2002. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 125: 765-772.
19. Leonard BE,. 2001. Changes in the immune system in depression and dementia: causal or co-incidental effects?. Int J Dev Neurosci 19: 305-312.
20. Li L, Holscher C,. 2007. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56: 384-402.
21. Licastro F, Pedrini S, Caputo L, et al,. 2000. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103: 97-102.
22. Lis CG, Gaviria M,. 1997. Vascular dementia, hypertension, and the brain. Neurol Res 19: 471-480.
23. Lopez OL, Wisniewski SR, Becker JT, et al,. 1999. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56: 1266-1272.
24. Luchsinger JA, Reitz C, Honig LS, et al,. 2005. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545-551.
25. Mariani E, Monastero R, Mecocci P,. 2007. Mild cognitive impairment: a systematic review. J Alzheimers Dis 12: 23-35.
26. Markesbery WR,. 2010. Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 19: 221-228.
27. McKhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
28. Mehlhorn G, Hollborn M, Schliebs R,. 2000. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 18: 423-431.
29. Mrak RE, Griffin WS,. 2005. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8: 369-375.
30. O'Leary DH, Polak JF, Kronmal RA, et al,. 1999. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340: 14-22.
31. Panza F, Solfrizzi V, Colacicco AM, et al,. 2004. Mediterranean diet and cognitive decline. Public Health Nutr 7: 959-963.
32. Solfrizzi V, Scafato E, Capurso C, et al,. 2010. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 81: 433-440.
33. Suryadevara V, Storey SG, Aronow WS, et al,. 2003. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 58: M859-M861.
34. Takechi R, Galloway S, Pallebage-Gamarallage MM, et al,. 2010. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 49: 159-170.
35. Tzourio C,. 2007. Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin Neurosci 9: 61-70.
36. Vilalta-Franch J, Lõpez-Pousa S, Turon-Estrada A, et al,. 2010. Syndromic association of behavioral and psychological symptoms of dementia in Alzheimer disease and patient classification. Am J Geriatr Psychiatry 18: 421-432.
37. Yudofsky SC, Silver JM, Jackson W, et al,. 1986. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143: 35-39.
38. Zuliani G, Guerra G, Ranzini M, et al,. 2007. High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia. Int J Geriatr Psychiatry 22: 305-311.